Table 5.
One, three and five-year recurrence-free survival rates and unadjusted recurrence hazard ratios and 95% confidence intervals by TSH groupings, demographic and clinical predictor factors.
| Variable | One Year Survival % (95% CI) | Three-Year Survival % (95% CI) | Five-Year Survival % (95% CI) | Hazard Ratio (95% CI) | p-Value |
|---|---|---|---|---|---|
| Age | |||||
| <50 | 100 | 97 (82, 99) | 97 (82, 99) | 1.00 | |
| 50–70 | 91 (85, 95) | 84 (76, 89) | 79 (69, 86) | 6.32 (0.86, 46.8) | 0.071 |
| >70 | 94 (87, 98) | 85 (74, 92) | 74 (47, 89) | 6.03 (0.78, 46.4) | 0.084 |
| BMI categories | |||||
| Normal weight | 100 | 92 (76, 97) | 81 (50, 94) | 1.00 | |
| Overweight | 87 (75, 94) | 81 (65, 90) | 71 (44, 86) | 2.15 (0.67, 6.85) | 0.166 |
| Obese | 94 (90, 97) | 87 (80, 91) | 84 (75, 90) | 1.34 (0.46, 3.89) | 0.701 |
| Social deprivation quintile | |||||
| Quintile 1 (Most deprived) | 94 (87, 97) | 84 (75, 90) | 84 (75, 90) | 1.00 | |
| Quintile 2 | 94 (84, 98) | 84 (70, 92) | 84 (70, 92) | 1.03 (0.45, 2.44) | 0.944 |
| Quintile 3 | 91 (75, 97) | 83 (63, 93) | 83 (63, 93) | 1.01 (0.37, 2.78) | 0.986 |
| Quintile 4 | 100 | 95 (72, 99) | 88 (57, 97) | 0.29 (0.07, 1.25) | 0.097 |
| Quintile 5 (Least deprived) | 86 (69, 94) | 86 (69, 94) | 56 (17, 83) | 1.50 (0.07, 1.25) | 0.380 |
| History of diabetes mellitus | |||||
| No | 94 (90, 97) | 89 (84, 93) | 82 (72, 89) | 1.00 | |
| Yes | 87 (74, 94) | 67 (47, 81) | 67 (47, 81) | 2.49 (1.26, 4.94) | 0.009 |
| History of hypothyroidism | |||||
| No | 93 (89, 95) | 85 (79, 89) | 78 (67, 85) | 1.00 | |
| Yes | 98 (84, 100) | 94 (78, 99) | 94 (78, 99) | 0.28 (0.07, 1.16) | 0.078 |
| Baseline TSH (mU/L) | |||||
| ≤4.5 | 93 (89, 96) | 85 (80, 90) | 79 (69, 86) | 1.00 | |
| >4.5 | 94 (79, 99) | 88 (64, 96) | 88 (64, 96) | 0.66 (0.20, 2.16) | 0.495 |
| Histological subtype | |||||
| Endometrioid | 96 (92, 97) | 91 (85, 94) | 89 (82, 93) | 1.00 | |
| Non-endometrioid | 83 (71, 90) | 67 (49, 79) | 33 (6.4, 64) | 4.56 (2.39, 8.69) | <0.001 |
| FIGO (2009) Stage | |||||
| Early Stage (I/II) | 97 (93, 98) | 90 (85, 94) | 84 (74, 91) | 1.00 | |
| Late stage (III/IV) | 71 (55, 83) | 59 (41, 73) | 59 (41, 73) | 5.55 (2.89, 10.7) | <0.001 |
| Grade | |||||
| 1 | 99 (95, 100) | 96 (88, 99) | 93 (78, 98) | 1.00 | |
| 2 | 97 (89, 99) | 88 (76, 94) | 88 (76, 94) | 3.22 (0.94, 11.0) | 0.062 |
| 3 | 80 (70, 88) | 67 (54, 77) | 49 (26, 69) | 13.64 (4.75, 39.2) | <0.001 |
| LVSI | |||||
| No | 97 (93, 98) | 93 (88, 96) | 88 (76, 94) | 1.00 | |
| Yes | 84 (75, 91) | 67 (54, 77) | 62 (46, 74) | 5.54 (2.83, 10.84) | <0.001 |
| Depth of myometrial invasion | |||||
| ≤50% | 97 (93, 99) | 92 (86, 96) | 86 (74, 93) | 1.00 | |
| >50% | 86 (77, 91) | 72 (60, 81) | 68 (53, 79) | 3.82 (1.98, 7.40) | <0.001 |
BMI—body mass index. CI—confidence interval. TSH—thyroid-stimulating hormone. LVSI—lymphovascular space invasion. Bold values denote statistical significance at the p < 0.05 level.